Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuxi AppTec CoWUXIF 81 Forward PE Ratio is 23.06 as of Jul. 15, 2026. GuruFocus rates WUXIF with a GF Score™ of 81/100 and a GF Value™ of $13.66 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 87 Medical Diagnostics & Research companies, Wuxi AppTec Co ranks better than 51.72% on this metric.
Wuxi AppTec Co (OTCPK:WUXIF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Wuxi AppTec Co Forward PE Ratio Related Terms
Wuxi AppTec Co Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Wuxi AppTec Co's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuxi AppTec Co Forward PE Ratio Chart
Wuxi AppTec Co Annual Data
Trend
2022-12
2024-12
2025-12
Forward PE Ratio
21.14
13.25
18.16
Wuxi AppTec Co Quarterly Data
2022-06
2022-09
2022-12
2023-06
2023-09
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
29.41
17.54
21.14
18.05
14.16
9.55
10.88
6.96
13.25
14.20
13.08
20.06
18.16
17.09
WUXIF vs TMO, DHR, IDXX: Forward PE Ratio Comparison
For the Diagnostics & Research subindustry, Wuxi AppTec Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co Forward PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Wuxi AppTec Co (WUXIF) has a Forward PE Ratio of 23.06 as of Jul. 15, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Wuxi AppTec Co and its competitors. According to the industry distribution chart, Wuxi AppTec Co ranks #42 out of 87 companies in the Medical Diagnostics & Research industry, placing it in the top 48.3%.
Is Wuxi AppTec Co's Forward PE Ratio too high?
Wuxi AppTec Co's current Forward PE Ratio is 23.06. The Medical Diagnostics & Research industry median Forward PE Ratio is 21.90. Wuxi AppTec Co's value of 23.06 is 5.3% above this industry median. Based on the distribution chart, Wuxi AppTec Co ranks #42 out of 87 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Wuxi AppTec Co has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's Forward PE Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Wuxi AppTec Co ranks #42 out of 87 companies for Forward PE Ratio. This puts Wuxi AppTec Co in the upper half of its industry. The industry median Forward PE Ratio is 21.90. Wuxi AppTec Co's value of 23.06 is 5.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Diagnostics & Research company?
The median Forward PE Ratio among Medical Diagnostics & Research companies is 21.90, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuxi AppTec Co's current Forward PE Ratio of 23.06 is 5.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Wuxi AppTec Co and its competitors. For the Medical Diagnostics & Research industry, the median Forward PE Ratio is 21.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuxi AppTec Co's current Forward PE Ratio is 23.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (WUXIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $13.66, compared to a current price of $20.94 — trading 53.3% above its estimated fair value. The current Forward PE Ratio is 23.06 and 5.3% above the Medical Diagnostics & Research industry median of 21.90. Wuxi AppTec Co's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Wuxi AppTec Co (WUXIF), the current Forward PE Ratio is 23.06 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuxi AppTec Co (WUXIF) Overvalued in 2026?
Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued.
The current stock price of $20.94 is trading 53.3% above its estimated GF Value™ of $13.66.
GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.
Key valuation signals for WUXIF:
Forward PE Ratio: 23.06
GF Value™: $13.66 vs. price of $20.94 (53.3% above fair value)
Industry Position: 5.3% above the Medical Diagnostics & Research median (#42 of 87)
No single metric tells the full story. See the WUXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
81GF Score
Get the complete analysis for WUXIF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WUXIF has been successfully added to your 
